Source-grounded facts extracted from ANAVEX LIFE SCIENCES CORP.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ANAVEX LIFE SCIENCES CORP. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“May 20, 2026, Anavex Life Sciences Corp. (the “Company”) received a delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as”
Felix Lauscher departed as Chief Operating Officer at ANAVEX LIFE SCIENCES CORP..
“On May 11, 2026, Felix Lauscher, who had held the title of Chief Operating Officer of Anavex Life Sciences Corp. (the “Company”) since March 1, 2026, departed from the Company as part of a broader reorganization of duties at the Company following the appointment of Dr. Terrie Kellmeyer as the Company’s Interim Chief Executive Officer.”
Terrie Kellmeyer was appointed as Interim Chief Executive Officer at ANAVEX LIFE SCIENCES CORP..
“On May 4, 2026, the Board appointed Terrie Kellmeyer, PhD as the Company's Interim Chief Executive Officer.”
Christopher Missling was terminated as Chief Executive Officer at ANAVEX LIFE SCIENCES CORP..
“On April 30, 2026, a special committee (the "Special Committee") composed of independent directors of the Board of Directors (the "Board") of Anavex Life Sciences Corp. (the "Company") terminated the employment of Christopher Missling, PhD as the Company's Chief Executive Officer for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between Dr. Missling and the Company, as amended and restated), effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy.”
ANAVEX LIFE SCIENCES CORP. reported financial results for its fiscal quarter ended March 31, 2024.
“On May 9, 2024, Anavex Life Sciences Corp. (the “ Company ”) issued a press release reporting financial results for its fiscal quarter ended March 31, 2024”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.